Research Analysts Issue Forecasts for GYRE Q1 Earnings

Key Points

• Noble Financial predicts Gyre Therapeutics will report earnings of $0.12 per share for Q1 2026, with subsequent quarterly estimates rising to $0.14 EPS by Q4 2026.
• Gyre Therapeutics' last earnings report revealed a loss of $0.01 per share against estimates, alongside a revenue shortfall of approximately $4 million.
• HC Wainwright has initiated coverage on Gyre Therapeutics with a "buy" rating and a price target set at $18.00.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Noble Financial issued their Q1 2026 earnings per share estimates for Gyre Therapeutics in a report released on Tuesday, September 9th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings of $0.12 per share for the quarter. Noble Financial also issued estimates for Gyre Therapeutics' Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.13 EPS and Q4 2026 earnings at $0.14 EPS.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). Gyre Therapeutics had a return on equity of 7.67% and a net margin of 4.08%.The business had revenue of $26.77 million for the quarter, compared to analyst estimates of $30.80 million.

Separately, HC Wainwright began coverage on Gyre Therapeutics in a report on Tuesday, August 26th. They set a "buy" rating and a $18.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Gyre Therapeutics currently has an average rating of "Buy" and an average price target of $18.00.

Gyre Therapeutics Stock Down 3.6%

Shares of GYRE stock traded down $0.29 during trading hours on Wednesday, reaching $7.83. 74,967 shares of the company's stock were exchanged, compared to its average volume of 94,607. Gyre Therapeutics has a fifty-two week low of $6.11 and a fifty-two week high of $19.00. The stock has a market capitalization of $754.11 million, a P/E ratio of 783.78 and a beta of 1.86. The business has a fifty day moving average price of $7.62 and a 200-day moving average price of $8.57.

Institutional Trading of Gyre Therapeutics

Several large investors have recently made changes to their positions in GYRE. Wells Fargo & Company MN grew its holdings in shares of Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after purchasing an additional 913 shares during the last quarter. Barclays PLC boosted its holdings in Gyre Therapeutics by 13.5% in the fourth quarter. Barclays PLC now owns 10,543 shares of the company's stock valued at $128,000 after acquiring an additional 1,255 shares during the last quarter. Northern Trust Corp boosted its holdings in Gyre Therapeutics by 9.1% in the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock valued at $1,251,000 after acquiring an additional 8,624 shares during the last quarter. Bank of America Corp DE boosted its holdings in Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock valued at $84,000 after acquiring an additional 1,996 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Gyre Therapeutics by 15,083.3% in the first quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock valued at $140,000 after acquiring an additional 1,810 shares during the last quarter. Institutional investors own 23.99% of the company's stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.